Syk kinase silencer - ZaBeCor Pharmaceuticals

Drug Profile

Syk kinase silencer - ZaBeCor Pharmaceuticals

Alternative Names: Excellair

Latest Information Update: 28 Jul 2015

Price : $50

At a glance

  • Originator University of Pennsylvania
  • Developer ZaBeCor Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Small interfering RNA
  • Mechanism of Action RNA interference; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Inflammation

Most Recent Events

  • 28 Jul 2015 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 28 Jul 2015 Discontinued - Phase-II for Asthma in USA (Inhalation)
  • 24 May 2006 Preclinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top